A deep-dive reference for pharma IP teams, ANDA filers, litigation counsel, and institutional investors. Updated 2025. What the Orange Book […]
The pharmaceutical industry loves a good narrative about convergence. Drugs are meeting devices. Biologics are meeting sensors. Software is meeting
Global Key Takeaways The WHO Essential Medicines List covers more than 500 drugs that health systems are expected to keep
Optimization of Pharmaceutical R&D Portfolios: Strategic IP Valuation and Risk Mitigation in Regulated Markets Pharmaceutical R&D requires a capital allocation
Mastering Strategic Decision-Making in the Pharmaceutical R&D Portfolio Read Post »
The transatlantic regulatory split between the U.S. Food and Drug Administration and the European Medicines Agency stopped being a compliance
The $800B Regulatory Divide: Why the FDA-EMA Gap Is Now a Commercial Strategy Problem Read Post »
Executive Summary: The Structural Redesign of an Industry The pharmaceutical sector, historically characterized by its defensive moats of intellectual property
Section 1: The Economic Architecture of Modern Drug Development The numbers that define pharmaceutical R&D productivity are brutal and well-documented.
Outsourcing Drug Development: The Definitive Pharma IP and Operations Playbook Read Post »
Introduction China’s pharmaceutical sector completed a structural transformation in less than a decade. The country that was processing the world’s
Part 1: What Branded Generics Are (and Why the Distinction Matters) Defining the Category A branded generic is a pharmaceutical
Branded Generics: The Profit Engine Behind Off-Patent Drug Strategy Read Post »
Sign in or create a free account to read this DrugPatentWatch article
